| Control |
T1 (presentation) |
T2 (12 h) |
T3 (24 h) |
T4 (36 h) |
T5 (14 days) | |
|---|---|---|---|---|---|---|
|
sCr (μmol/L) |
88.4 (44.2–150.3) |
70.7 (53–106) |
61.88 (53–97.2) |
66.3 (44.2–88.4) |
70.7 (44.2–97.2) |
79.6 (53–123.8) |
|
SDMA (μmol/L) |
0.54 (0.35–0.74) |
0.5 (0.35–0.64) |
0.47 (0.25–0.64) |
0.45 (0.25–0.64) |
0.4 (0.25–0.69) |
0.54 (0.3–0.84) |
|
uKIM-1/uCr (ng/mg) |
0.13 (0.013–0.36) |
0.13 (0.001–0.2) |
0.15 (0.002–0.32) |
0.20 (0.008–0.35) |
0.14 (0.03–0.25) | |
|
uOPN/uCr (ng/mg) |
1.86 (0.13–4.2) |
2.54 (0.08–7.96) |
5.22 (0.22–24.87) |
6.34 (0.5–31.86) |
1.88 (0.26–15.46) | |
|
uCysC/uCr (ng/mg) |
0.95 (0.16–3.74) |
0.66 (0.22–1.43) |
0.57 (0.17–2.94) |
0.56 (0.24–1.78) |
0.58 (0.17–2.39) | |
|
uNGAL/uCr (ng/mg) |
0.21 (0.02–2.94) |
2.8 (0.1–15.78) |
2.1 (0.07–3.02) |
2.62 (0.09–21.66) |
0.28 (0.03–23.3) | |
|
uMCP-1/uCr (ng/mg) |
0.46 (0.05–1.97) |
0.8 (0.15–5.44) |
0.78 (0.23–7.24) |
0.88 (0.27–5.58) |
0.6 (0.09–6.14) | |
|
uGGT/uCr (U/g) |
15.4 (0.95–75.26) |
30.14 (3.96–83.44) |
21.6 (0–85.65) |
28.52 (9–120.5) |
18.27 (0–48.83) | |
|
uALB/uCr mg/g |
0.005 (0.002–6) 32/34 (94.1%) < LOQ* |
0.019 (0.03–289) 9/16 (56%) < LOQ |
0.036 (0.004–116) 16/25 (64%) <LOQ |
0.025 (0.01–175) 17/22 (77%) < LOQ |
0.007 (0.004–124) 16/19 (84%) < LOQ | |
|
uIL-8/uCr (ng/mg) |
0.06 (0.02–0.9) 18/34 (52.9%) < LOQ** |
0.08 (0.02–0.29) 10/16 (62.5%) < LOQ |
0.14 (0.03–1.62) 21/24 (87.5%) < LOQ |
0.14 (0.05–0.79) 18/22 (81.8%) < LOQ |
0.07 (0.03–3.37) 14/20 (70%) < LOQ | |
|
uALP/uCr (U/g) | 100% < LOQ*** | 100% < LOQ | 100% < LOQ | 96% < LOQ | 100% < LOQ |